Zobrazeno 1 - 10
of 48
pro vyhledávání: '"базисные противовоспалительные препараты"'
Publikováno v:
Современная ревматология, Vol 16, Iss 2, Pp 13-20 (2022)
Objective: to compare the course of the disease and therapy in rheumatoid arthritis (RA) patients who meet and do not meet the criteria for difficult- to-treat RA (D2T).Patients and methods. The study included RA patients who met the 2010 ACR/EULAR c
Externí odkaz:
https://doaj.org/article/37fc17336e28484f825f0aadf327da6d
Autor:
E. Yu. Loginova, T. V. Korotaeva
Publikováno v:
Современная ревматология, Vol 16, Iss 1, Pp 7-13 (2022)
The article presents an analysis of literature data on the use of a new group of targeted synthetic disease-modifying antirheumatic drugs (DMARDs) Janus kinase (JAK) inhibitors – tofacitinib (TOFA) and upadacitinib (UPA) – in psoriatic arthritis
Externí odkaz:
https://doaj.org/article/9e39c724b8e144acaf368ef7f0b829d5
Autor:
G. I. Gridneva, B. S. Belov
Publikováno v:
Современная ревматология, Vol 15, Iss 6, Pp 7-12 (2021)
According to experts, the human immunodeficiency virus (HIV) epidemic has a steady downward trend, but the attention of the medical community to this problem is not waning. Before the introduction of highly active antiretroviral therapy, the prevalen
Externí odkaz:
https://doaj.org/article/c153f8b8f0ab4778a65d348ca6d35a6a
Autor:
T. V. Korotaeva, E. Yu. Loginova, E. E. Gubar, Yu. L. Korsakova, M. V. Sedunova, I. N. Pristavsky, I. N. Kushnir, I. F. Umnova, S. S. Kudishina
Publikováno v:
Современная ревматология, Vol 15, Iss 1, Pp 27-31 (2021)
The goal of psoriatic arthritis (PsA) therapy is to achieve remission or minimal disease activity (MDA). According to the EULAR guidelines, synthetic disease-modifying antirheumatic drugs (sDMARDs), methotrexate (MTX) in particular, are first-line th
Externí odkaz:
https://doaj.org/article/0b9bec69cbf34c87a03b52e876a157db
Autor:
Ye. D. Yehudina, S. A. Trypolka
Publikováno v:
Современная ревматология, Vol 15, Iss 1, Pp 79-86 (2021)
Enthesitis is a common clinical feature of spondyloarthritis (SpA), characterized by inflammation of the tendon or ligament attachment site to a bone or joint capsule. The importance of detecting enthesitis for the diagnosis of SpA is confirmed by it
Externí odkaz:
https://doaj.org/article/c6136ed13bcb42c6a83bcf9a9d003280
Publikováno v:
Современная ревматология, Vol 14, Iss 4, Pp 103-110 (2020)
The review considers the problem of comorbid infections (CIs) in ankylosing spondylitis and psoriatic arthritis (PsA) as the main nosological entities of spondyloarthritis (SpA). It analyzes the frequency of CIs during therapy with biological agents
Externí odkaz:
https://doaj.org/article/997177a653bd48b1bbebbe60a0a22a7a
Autor:
E. Yu. Loginova, T. V. Korotaeva, E. E. Gubar, Yu. L. Korsakova, S. I. Glukhova, E. A. Vasilenko, A. A. Vasilenko, N. A. Kuznetsova, I. M. Patrikeyeva, E. L. Nasonov
Publikováno v:
Современная ревматология, Vol 15, Iss 3 (2021)
Objective: to compare the clinical efficacy in real clinical practice of the targeted synthetic disease-modifying antirheumatic drug (sDMARD) tofacitinib (TOFA) and the biologic DMARD (bDMARD), an inhibitor of tumor necrosis factor alpha (TNFα), ada
Externí odkaz:
https://doaj.org/article/a93ceb85d4554e998f0f769a4d919a0f
Autor:
N. V. Chichasova
Publikováno v:
Современная ревматология, Vol 12, Iss 4, Pp 65-70 (2018)
The possibilities of rheumatoid arthritis therapy have been significantly expanded today. In addition to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), biologic agents (BAs), and a targeted synthetic DMARD, a control treatme
Externí odkaz:
https://doaj.org/article/12ff5fce0d56426d923aacec3cfdc99c
Autor:
Yu. V. Muraviev, G. I. Gridneva, L. A. Muravieva, N. V. Muravieva, A. V. Alexeeva, K. S. Nurbaeva, K. M. Mikhailov, A. V. Rozov
Publikováno v:
Современная ревматология, Vol 12, Iss 4, Pp 101-105 (2018)
Objective: to analyze the reasons for discontinuation of traditional disease-modifying antirheumatic drugs (tDMARDs), biologic agents (BAs), and tofacitinib (TOFA) in patients with rheumatoid arthritis (RA) in real clinical practice.Patients and meth
Externí odkaz:
https://doaj.org/article/54af7ccaf94d4b04a8ba9c3d7d9428d9
Autor:
Yu. V. Muravyev, L. A. Muravyeva
Publikováno v:
Современная ревматология, Vol 12, Iss 3, Pp 120-123 (2018)
The paper discusses the problem of laboratory monitoring in therapy with disease-modifying antirheumatic drugs (DMARDs) and biological agents (BAs) in patients with rheumatoid arthritis (RA). Due to the risk of adverse reactions, in particular to tha
Externí odkaz:
https://doaj.org/article/d076e395abaa4ee8bcbe173b609b9284